Clinical Trials Logo

Filter by:
NCT ID: NCT00232258 Completed - Ulcerative Colitis Clinical Trials

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study

NICE
Start date: April 2005
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic mucosal appearance of two doses of SR140333B against placebo in patients with mild to moderate ulcerative colitis resistant to treatment with 5-ASA.

NCT ID: NCT00231114 Completed - Asthma Clinical Trials

Asthma Intervention Research 2 (AIR2) Trial

Start date: September 2005
Phase: N/A
Study type: Interventional

The objective of this randomized, double blind, sham-controlled study is to demonstrate the safety and effectiveness of the Alair System in a population of subjects with severe asthma who are still symptomatic despite being managed on conventional therapy of high doses of inhaled corticosteroids and long-acting β2-agonists. The primary efficacy endpoint will be the difference between Study groups in the change in Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from the 6-, 9-, and 12-month follow-up visits. All other outcome measures assessed at 12 months post-treatment. This will be a multicenter, randomized, double-blind, sham-controlled study comparing the effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA). A Bayesian adaptive approach to sample size selection is used with a randomization scheme of 2:1 (two Alair Group Subjects for every one Control Group Subject).

NCT ID: NCT00229697 Completed - Breast Neoplasms Clinical Trials

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Start date: October 2003
Phase: Phase 2
Study type: Interventional

This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

NCT ID: NCT00227695 Completed - Lymphoma Clinical Trials

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

Start date: June 8, 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether giving rituximab over a short period of time is more effective than giving it over a long period of time in treating follicular non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying rituximab to see how well it works when given over a short period of time compared to when given over a long period of time in treating patients with follicular non-Hodgkin's lymphoma.

NCT ID: NCT00219622 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease

NCT ID: NCT00216190 Completed - Clinical trials for Mechanically Ventilated and Intubated Subjects

A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation

Start date: March 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.

NCT ID: NCT00211068 Completed - Clinical trials for Pure Red-cell Aplasia

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Start date: March 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (EPO) antibody positive pure red cell aplasia (PRCA) in participants with chronic kidney disease who have been recently treated with epoetin alfa (EPREX).

NCT ID: NCT00211042 Completed - Clinical trials for Pure Red-cell Aplasia

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Start date: February 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to investigate the relationship of anti-erythropoietin antibodies to the clinical course and outcome of pure red cell aplasia (PRCA) in participants currently or previously treated with recombinant human erythropoietin.

NCT ID: NCT00210639 Completed - Clinical trials for Musculoskeletal Diseases

A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection

Start date: August 2002
Phase: Phase 3
Study type: Observational

The purpose of this study is to assess the long-term safety of levofloxacin administered to children as therapy for acute bacterial infection.

NCT ID: NCT00207337 Completed - Emphysema Clinical Trials

Exhale (R) Stent for Emphysema

Start date: July 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation. Highly invasive procedures such as lung volume reduction surgery or lung transplantation are also performed. Treatment using the Exhale Drug-Eluting Stent (DES) is a minimally invasive bronchoscopic treatment that has the potential to reduce shortness of breath in emphysema patients. This study tests the safety and effects of Exhale DES in the treatment of patients with emphysema.